Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Cardiovascular >> Lipids / Lipoproteins >> Fatty Acids >> Synthesis
Overview
Product name
Anti-Agpat2 antibody
See all Agpat2 products (3) ...
Description
Rabbit polyclonal to Agpat2
Tested applications
WB, ELISAmore details
Cross reactivity
Reacts with
Human
Immunogen
A region within synthetic peptide: IPTSGLTAAD VPALVDTCHR AMRTTFLHIS KTPQENGATA GSGVQPAQ, corresponding to C terminal amino acids 199-246 of Human Agpat2
IPTSGLTAAD VPALVDTCHR AMRTTFLHIS KTPQENGATA GSGVQPAQ
Positive control
Jurkat cell lysate.
Properties
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage buffer
Preservative: None
Constituents: 2% Sucrose, PBS
Concentration
Concentration information loading...
Purity
Protein A purified
Clonality
Polyclonal
Isotype
IgG
Research areas
Cancer >> Cancer Metabolism >> Metabolic signaling pathway >> Metabolism of lipids and lipoproteins
Cardiovascular >> Lipids / Lipoproteins >> Fatty Acids >> Synthesis
-
Western blot - Agpat2 antibody (ab62599)
(enlarge)
Applications
Show applications key
Our Abpromise guarantee covers the use of ab62599 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- 1 Image
WB
ELISA
Application notes
ELISA: Use at an assay dependent dilution.
ELISA titre using peptide based assay: 1/312500.
WB: Use at a concentration of 5 µg/ml. Detects a band of approximately 31 kDa (predicted molecular weight: 31 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Target
Function
Converts lysophosphatidic acid (LPA) into phosphatidic acid by incorporating an acyl moiety at the sn-2 position of the glycerol backbone.
Tissue specificity
Expressed predominantly in heart and liver.
Pathway
Phospholipid metabolism; CDP-diacylglycerol biosynthesis; CDP-diacylglycerol from sn-glycerol 3-phosphate: step 2/3.
Involvement in disease
Defects in AGPAT2 are the cause of congenital generalized lipodystrophy type 1 (CGL1) [MIM:608594]; also known as Berardinelli-Seip congenital lipodystrophy type 1 (BSCL1) or Berardinelli-Seip syndrome. CGL1 is an autosomal recessive disorder characterized by marked paucity of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes.
Sequence similarities
Belongs to the 1-acyl-sn-glycerol-3-phosphate acyltransferase family.
Domain
The HXXXXD motif is essential for acyltransferase activity and may constitute the binding site for the phosphate moiety of the glycerol-3-phosphate.
Cellular localization
Membrane.
Target information above from: UniProt accessionO15120
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Alternative names
- 1 acyl sn glycerol 3 phosphate acyltransferase beta antibody
- 1 acylglycerol 3 phosphate O acyltransferase 2 antibody
- 1 AGP acyltransferase 2 antibody
see all
Database links
- Entrez Gene: 10555 Human
- Omim: 603100 Human
- SwissProt: O15120 Human
- Unigene: 320151 Human
Anti-Agpat2 antibody images:
Western blot - Agpat2 antibody (ab62599)
Lane 1 : Molecular weight marker
Lane 2 : Anti-Agpat2 antibody (ab62599) at 5 µg/ml
Lane 1 : As above
Lane 2 : Jurkat cell lysate at 10 µg
Secondary
Lane 2 : HRP conjugated anti-Rabbit IgG at 1/50000 dilution
Predicted band size : 31 kDa
Observed band size : 31 kDa
Gel concentration 12%
References for Anti-Agpat2 antibody (ab62599)
ab62599 has not yet been referenced specifically in any publications.
Publishing research using ab62599? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"